Patients with metastatic prostate cancer may benefit from biologic medication-device combination immunotherapy.

Published Date: 10 Apr 2024

Patients with metastatic castrate-resistant tumors showed multiple clinical responses to SYNC-T, an experimental treatment that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.

2.

Study identifies new approach to protect the brain during radiation therapy

3.

While most cancer screenings won't prolong lives, there are still good reasons to continue screening.

4.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

5.

Radiation therapy for patients with breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot